Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park S.C. | - |
dc.contributor.author | Chun H.J. | - |
dc.contributor.author | Jung S.W. | - |
dc.contributor.author | Keum B. | - |
dc.contributor.author | Han W.S. | - |
dc.contributor.author | Choung R.S. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Jeen Y.T. | - |
dc.contributor.author | Lee H.S. | - |
dc.contributor.author | Um S.H. | - |
dc.contributor.author | Lee S.W. | - |
dc.contributor.author | Choi J.H. | - |
dc.contributor.author | Kim C.D. | - |
dc.contributor.author | Ryu H.S. | - |
dc.contributor.author | Hyun J.H. | - |
dc.date.available | 2020-11-03T17:51:04Z | - |
dc.date.issued | 2004-09 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20808 | - |
dc.description.abstract | BACKGROUND/AIMS: As a second-line treatment for H. pylori eradication in the case of first-line OAC (omeprazole, amoxicillin, clarithromycin) treatment failure, a minimum of one-week OBMT quadruple therapy composed of omeprazole, bismuth, metronidazole, tetracycline has been recommended in European countries and one or two weeks in USA. In Korea, one-week OBMT quadruple therapy is recommended for the case of first-line OAC treatment failure. Because H. pylori eradication rate of one-week OBMT therapy in Korea is about 80%, the eradication rate of one week therapy is not satisfactory. We analyzed the effect of two-week second-line OBMT therapy. METHODS: Between June 2002 and June 2003, 107 patients who were H. pylori positive (44 males and 63 females: mean age 51.8 years) after primary eradication therapy received two-week OBMT therapy. Four weeks after completion of therapy, 13C-urea breath test was performed to detect H. pylori. RESULTS: After two weeks of OBMT therapy, eradication was achieved in 103 of 107 patients (96.3%) and in 68 of 71 peptic ulcer patients (95.8%). CONCLUSIONS: Two-week OBMT therapy should be considered as a retreatment regimen with the eradication rate more than 90%. | - |
dc.format.extent | 6 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.scopusid | 2-s2.0-21644455056 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology, v.44, no.3, pp 136 - 141 | - |
dc.citation.title | The Korean journal of gastroenterology | - |
dc.citation.volume | 44 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 136 | - |
dc.citation.endPage | 141 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001108711 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | antacid agent | - |
dc.subject.keywordPlus | antiinfective agent | - |
dc.subject.keywordPlus | antiulcer agent | - |
dc.subject.keywordPlus | bismuth | - |
dc.subject.keywordPlus | metronidazole | - |
dc.subject.keywordPlus | omeprazole | - |
dc.subject.keywordPlus | tetracycline | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | Helicobacter infection | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | retreatment | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Antacids | - |
dc.subject.keywordPlus | Anti-Bacterial Agents | - |
dc.subject.keywordPlus | Anti-Ulcer Agents | - |
dc.subject.keywordPlus | Bismuth | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Helicobacter Infections | - |
dc.subject.keywordPlus | Helicobacter pylori | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Metronidazole | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Omeprazole | - |
dc.subject.keywordPlus | Retreatment | - |
dc.subject.keywordPlus | Tetracycline | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Retreatment | - |
dc.subject.keywordAuthor | Eradication | - |
dc.subject.keywordAuthor | 재치료 | - |
dc.subject.keywordAuthor | 제균율 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.